NatureWise Biotech & Medicals Corporation
NatureWise Biotech & Medicals Corporation engages in the research and development of Western medicine, Chinese medicine, and biotechnology in Taiwan. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; and green propolis and red yeast rice products. The company was founded in 1990 and is headquartered in Taipei, Taiwan.
NatureWise Biotech & Medicals Corporation (4732) - Total Assets
Latest total assets as of June 2025: NT$786.70 Million TWD
Based on the latest financial reports, NatureWise Biotech & Medicals Corporation (4732) holds total assets worth NT$786.70 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NatureWise Biotech & Medicals Corporation - Total Assets Trend (2016–2024)
This chart illustrates how NatureWise Biotech & Medicals Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NatureWise Biotech & Medicals Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
NatureWise Biotech & Medicals Corporation's total assets of NT$786.70 Million consist of 91.7% current assets and 8.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 38.1% |
| Accounts Receivable | NT$56.73 Million | 6.8% |
| Inventory | NT$84.36 Million | 10.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$22.85 Million | 2.7% |
| Goodwill | NT$8.54 Million | 1.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how NatureWise Biotech & Medicals Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NatureWise Biotech & Medicals Corporation's current assets represent 91.7% of total assets in 2024, an increase from 89.2% in 2016.
- Cash Position: Cash and equivalents constituted 38.1% of total assets in 2024, up from 7.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 10.0% of total assets.
NatureWise Biotech & Medicals Corporation Competitors by Total Assets
Key competitors of NatureWise Biotech & Medicals Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
NatureWise Biotech & Medicals Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - NatureWise Biotech & Medicals Corporation generates 0.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, NatureWise Biotech & Medicals Corporation generates $ 0.11 in net profit.
NatureWise Biotech & Medicals Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.89 | 12.46 | 9.45 |
| Quick Ratio | 10.51 | 11.07 | 8.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$659.39 Million | NT$ 579.59 Million | NT$ 512.86 Million |
NatureWise Biotech & Medicals Corporation - Advanced Valuation Insights
This section examines the relationship between NatureWise Biotech & Medicals Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.37 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 20.4% |
| Total Assets | NT$840.59 Million |
| Market Capitalization | $19.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values NatureWise Biotech & Medicals Corporation's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: NatureWise Biotech & Medicals Corporation's assets grew by 20.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NatureWise Biotech & Medicals Corporation (2016–2024)
The table below shows the annual total assets of NatureWise Biotech & Medicals Corporation from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$840.59 Million | +20.35% |
| 2023-12-31 | NT$698.45 Million | +0.84% |
| 2022-12-31 | NT$692.60 Million | -1.70% |
| 2021-12-31 | NT$704.57 Million | +7.04% |
| 2020-12-31 | NT$658.24 Million | +8.51% |
| 2019-12-31 | NT$606.64 Million | +98.16% |
| 2018-12-31 | NT$306.14 Million | -0.68% |
| 2017-12-31 | NT$308.23 Million | -12.11% |
| 2016-12-31 | NT$350.69 Million | -- |